Legal & General Group Plc raised its stake in shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) by 26.6% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 11,354 shares of the biotechnology company’s stock after purchasing an additional 2,383 shares during the period. Legal & General Group Plc’s holdings in Heron Therapeutics were worth $157,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Wells Fargo & Company MN lifted its holdings in Heron Therapeutics by 78.8% during the first quarter. Wells Fargo & Company MN now owns 39,579 shares of the biotechnology company’s stock valued at $595,000 after purchasing an additional 17,442 shares in the last quarter. FMR LLC lifted its holdings in Heron Therapeutics by 36.7% during the first quarter. FMR LLC now owns 8,030,880 shares of the biotechnology company’s stock valued at $120,464,000 after purchasing an additional 2,158,041 shares in the last quarter. Point72 Asset Management L.P. purchased a new position in Heron Therapeutics during the first quarter valued at $2,002,000. Teachers Advisors LLC lifted its holdings in Heron Therapeutics by 20.5% during the first quarter. Teachers Advisors LLC now owns 69,720 shares of the biotechnology company’s stock valued at $1,046,000 after purchasing an additional 11,862 shares in the last quarter. Finally, Swiss National Bank lifted its holdings in Heron Therapeutics by 39.9% during the first quarter. Swiss National Bank now owns 72,600 shares of the biotechnology company’s stock valued at $1,089,000 after purchasing an additional 20,700 shares in the last quarter.

TRADEMARK VIOLATION NOTICE: This news story was first reported by Daily Political and is the property of of Daily Political. If you are accessing this news story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright laws. The legal version of this news story can be read at https://www.dailypolitical.com/2017/10/15/heron-therapeutics-inc-hrtx-holdings-boosted-by-legal-general-group-plc.html.

HRTX has been the topic of several recent analyst reports. Cantor Fitzgerald set a $31.00 price objective on shares of Heron Therapeutics and gave the company a “buy” rating in a report on Friday, August 18th. Jefferies Group LLC reaffirmed a “buy” rating on shares of Heron Therapeutics in a report on Wednesday, August 16th. Noble Financial reaffirmed a “buy” rating on shares of Heron Therapeutics in a report on Thursday, August 10th. Cowen and Company set a $40.00 price objective on shares of Heron Therapeutics and gave the company a “buy” rating in a report on Thursday, August 3rd. Finally, Aegis reaffirmed a “buy” rating and set a $33.00 price objective on shares of Heron Therapeutics in a report on Tuesday, July 18th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and eleven have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $28.50.

Heron Therapeutics, Inc. (NASDAQ HRTX) opened at 15.40 on Friday. The stock’s market capitalization is $833.73 million. The stock has a 50 day moving average of $15.97 and a 200 day moving average of $15.18. Heron Therapeutics, Inc. has a 1-year low of $12.21 and a 1-year high of $20.85.

Heron Therapeutics (NASDAQ:HRTX) last issued its quarterly earnings data on Wednesday, August 9th. The biotechnology company reported ($0.80) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.90) by $0.10. The business had revenue of $8.51 million during the quarter, compared to analyst estimates of $4.53 million. On average, analysts expect that Heron Therapeutics, Inc. will post ($3.51) earnings per share for the current year.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

Want to see what other hedge funds are holding HRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Heron Therapeutics, Inc. (NASDAQ:HRTX).

Institutional Ownership by Quarter for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Ratings for Heron Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.